Revitalizing the U.S. National HIV/AIDS Strategy
Meeting Report and Action Plan
15 April 2013 - On December 11–12, 2012, in Washington, D.C., Treatment Action Group (TAG) hosted a meeting of HIV advocates, service providers, and researchers from across the United States (U.S.) to review the current state of the national HIV response and discuss how to revitalize the National HIV/AIDS Strategy (NHAS). Meeting participants reviewed the latest data, discussed the changing landscape of the HIV response, and developed recommendations for continued and expedited progress. The Meeting Report summarizes the presentations and discussions, and outlines the key recommendations from participants. The Action Plan incorporates the recommendations from the meeting report.
- Advancing Research, Securing Access
- Ryan White at a Crossroads
- The "G" Word
- TB Drugs for Children
- Razing the House of Cards
- Preparing for Generics
- Undetectable Is Not Always Enough
- Sanofi’s Double-Edged Sword
- A Necessary Transformation
- Help Paying for HIV and Hepatitis Treatment
Hepatitis C and the IL28B Gene
April 2013 - This fact sheet describes how the genetic factor IL28B affects responses to hepatitis C treatment, including poorer efficacy among African Americans and people of African ancestry. Available in English and Spanish.
We Can Heal: Prevention, Diagnosis, Treatment, Care, and Support:
Addressing Drug-Resistant Tuberculosis in Children
March 21, 2013 - This collection calls for urgent attention to the global problem of pediatric drug-resistant tuberculosis (DR-TB). The stories of 30 children with DR-TB in 30 countries are a testament to the need for improved programs, policies, and tools to reach the goal of zero TB deaths, new infections, and suffering.
An Activist’s Guide to Bedaquiline (Sirturo)
March 11, 2013 - People with drug-resistant TB must resort to second-line drugs, which are more toxic, less effective, and more expensive. However, in December 2012, a new drug called bedaquiline was approved for the treatment of multidrug-resistant TB (MDR-TB). Bedaquiline (also known by its trade name, Sirturo, or as TMC207) is the first new drug from a new drug class to treat TB to be approved by the United States Food and Drug Administration (FDA) in over 40 years. This guide highlights important safety and efficacy data reported thus far and offers advocacy recommendations for activists to take forward.
Funding Scientific Innovation: Global Investments in HIV Treatment Research and Development in 2010 and 2011
6 March, 2013 - Advances in HIV treatment research in 2010 and 2011 saw improvement in treatment regimens and strategies, and reinvigorated optimism for finding a cure. In 2012, TAG and AVAC, with financial support from UNAIDS, put forth a collaborative effort to analyze investment trends in HIV treatment research and development (R&D) in 2010 and 2011.
Guide to Clinical Trials for People with Hepatitis C (Second Edition)
January 2013 - There are many new hepatitis C drugs being studied in clinical trials. People with hepatitis C have many options to choose from. Whether you have hepatitis C or another medical condition, deciding to participate in a clinical trial can be complicated. Having more information can help you decide whether or not to participate in a clinical trial, and which trial, or trials, may be right for you. This guide is available in English and Spanish.